Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

BIOCON's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.136000
forwardPE 32.271214
debtToEquity 66.259000
earningsGrowth 1.550000
revenueGrowth 0.128000
grossMargins 0.605710
operatingMargins 0.159770
trailingEps 8.480000
forwardEps 9.920000

A current ratio of 1.136 for Biocon Limited implies that the company has ample liquidity to meet its short-term debts. Biocon Limited's cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
Positive earnings and revenue growth for BIOCON suggest that the company is positioned for business expansion. The company's strong financial performance indicates sustained growth, as increasing sales and profits fuel its future success.
Biocon Limited's forward EPS being higher than its trailing EPS signals anticipated growth in profitability for the current financial year. This suggests that Biocon Limited is on track to improve its earnings, outpacing the previous year's performance and reflecting positive market expectations.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's stock price has repeatedly hovered near the lower end of projections. This trend indicates that the company may be facing obstacles in achieving the growth anticipated by analysts.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have shown a buy bias for BIOCON, signaling it as a strong investment choice. This positive outlook could motivate investors to allocate funds to BIOCON, seeing it as a reliable and potentially profitable option, especially in an environment where the stock market is highly scrutinized.